Search research articles
Contact Us
Filters
Showing results (1-10 of 113) with videos related to
Page
of 12
Sort By:
The Journal of Experimental Medicine
|
October 26, 2011
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks
Francesca Pellicano, Tessa L Holyoake
Blood
|
February 5, 2017
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L Holyoake, David Vetrie
Cancer Biomarkers : Section a of Disease Markers
|
October 6, 2007
Stem cells in chronic myeloid leukaemia
Francesca Pellicano, Tessa L Holyoake
Hematological Oncology
|
April 19, 2007
Therapeutic targets in chronic myeloid leukaemia
Nicholas B Heaney, Tessa L Holyoake
Immunological Reviews
|
December 17, 2014
Do we need more drugs for chronic myeloid leukemia?
Tessa L Holyoake, G Vignir Helgason
Cancer
|
October 10, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
Mark W Drummond, Tessa L Holyoake
Blood
|
October 26, 2013
Redirecting traffic using the XPO1 police
Sheela A Abraham, Tessa L Holyoake
Experimental Hematology
|
December 27, 2016
Preclinical approaches in chronic myeloid leukemia: from cells to systems
Cassie J Clarke, Tessa L Holyoake
Cell Cycle (Georgetown, Tex.)
|
September 1, 2016
Casting a NETwork instead of shooting magic bullets
Sheela A Abraham, Tessa L Holyoake
Cell
|
September 24, 2016
Lifting the Differentiation Embargo
Anne-Louise Latif, Tessa L Holyoake
Page
of 12
Search research articles
Search
Showing results (1-10 of 113) with videos related to
Sort By:
Page
of 12
The Journal of Experimental Medicine
|
October 26, 2011
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks
Francesca Pellicano, Tessa L Holyoake
Blood
|
February 5, 2017
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L Holyoake, David Vetrie
Cancer Biomarkers : Section a of Disease Markers
|
October 6, 2007
Stem cells in chronic myeloid leukaemia
Francesca Pellicano, Tessa L Holyoake
Hematological Oncology
|
April 19, 2007
Therapeutic targets in chronic myeloid leukaemia
Nicholas B Heaney, Tessa L Holyoake
Immunological Reviews
|
December 17, 2014
Do we need more drugs for chronic myeloid leukemia?
Tessa L Holyoake, G Vignir Helgason
Cancer
|
October 10, 2003
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
Mark W Drummond, Tessa L Holyoake
Blood
|
October 26, 2013
Redirecting traffic using the XPO1 police
Sheela A Abraham, Tessa L Holyoake
Experimental Hematology
|
December 27, 2016
Preclinical approaches in chronic myeloid leukemia: from cells to systems
Cassie J Clarke, Tessa L Holyoake
Cell Cycle (Georgetown, Tex.)
|
September 1, 2016
Casting a NETwork instead of shooting magic bullets
Sheela A Abraham, Tessa L Holyoake
Cell
|
September 24, 2016
Lifting the Differentiation Embargo
Anne-Louise Latif, Tessa L Holyoake
Page
of 12